Research Article
Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging

Norbert Schuff, Shinji Matsumoto, Joseph Kmiecik, Colin Studholme, Antao Du, Frank Ezekiel, Bruce L. Miller, Joel H. Kramer, William J. Jagust, Helen C. Chui and Michael W. Weiner

Alzheimer`s & Dementia, 2009, 5(6), 454-462. DOI: 10.1016/j.jalz.2009.04.1233

Abstract

Background Our objectives were to compare the effects of subcortical ischemic vascular dementia (SIVD) and Alzheimer's disease (AD) on cerebral blood flow (CBF), and then to analyze the relationship between CBF and subcortical vascular disease, measured as volume of white-matter lesions (WMLs). Methods Eight mildly demented patients with SIVD (mean ± SD; aged 77 ± 8 years; Mini-Mental State Examination score 26 ± 3 years) and 14 patients with AD were compared with 18 cognitively normal elderly subjects. All subjects had CBF measured using arterial spin-labeling magnetic resonance imaging, and brain volumes were assessed using structural magnetic resonance imaging. Results AD and SIVD showed marked CBF reductions in the frontal (P = 0.001) and parietal (P = 0.001) cortices. In SIVD, increased subcortical WMLs were associated with reduced CBF in the frontal cortex (P = 0.04), in addition to cortical atrophy (frontal, P = 0.05; parietal, P = 0.03). Conclusions Subcortical vascular disease is associated with reduced CBF in the cortex, irrespective of brain atrophy.

ASCI-ID: 285-94

View Fulltext

Similar Articles


Transcranial Doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 445-455. DOI: 10.1016/j.jalz.2010.09.002

Update on the Magnetic Resonance Imaging core of the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2010, 6(3), 212-220. DOI: 10.1016/j.jalz.2010.03.004

Addressing population aging and Alzheimer’s disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer’s Disease Neuroimaging Initiative

Alzheimer`s & Dementia, 2010, 6(3), 291-296. DOI: 10.1016/j.jalz.2010.03.009

Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer‘s disease study cohorts from phase 3 trials of semagacestat and solanezumab

Alzheimer`s & Dementia, 2011, 7(4), 396-401. DOI: 10.1016/j.jalz.2011.05.2353

Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 425-435. DOI: 10.1016/j.jalz.2010.09.003

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007

Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer‘s disease

Alzheimer`s & Dementia, 2011, 7(4), 474-485. DOI: 10.1016/j.jalz.2011.04.007

Comparing new templates and atlas-based segmentations in the volumetric analysis of brain magnetic resonance images for diagnosing Alzheimer‘s disease

Alzheimer`s & Dementia, 2012, 8(5), 399-406. DOI: 10.1016/j.jalz.2011.07.002

Global gray matter changes in posterior cortical atrophy: A serial imaging study

Alzheimer`s & Dementia, 2012, 8(6), 502-512. DOI: 10.1016/j.jalz.2011.09.225

Vascular disease and dementias: Paradigm shifts to drive research in new directions

Alzheimer`s & Dementia, 2013, 9(1), 76-92. DOI: 10.1016/j.jalz.2012.02.007

Homocysteine, progression of ventricular enlargement, and cognitive decline: The Second Manifestations of ARTerial disease–Magnetic Resonance study

Alzheimer`s & Dementia, 2013, 9(3), 302-309. DOI: 10.1016/j.jalz.2011.11.008